Huntingdon, United Kingdom (PressExposure) July 23, 2009 -- Cellexus Limited, 'The Cell Company', is delighted to announce the appointment of Dr Sandy Primrose as a Non-Executive Director. His appointment further enhances the extensive commercial experience of the Board members and adds key expertise in the biopharmaceutical sector which will be of significant strategic importance in management of the Company's growth.
Cellexus Limited is a leading supplier of innovative single use, disposable bioreactors which are designed to improve cell culture processes and enable production of higher yields of soluble proteins. The CellMaker systems the Company supplies apply single-use, disposable cell culture bioreactor bags with highly efficient methods to mix and oxygenate. Whilst other systems require shakers, rockers, rollers or large environmental chambers, the CellMaker systems employ a novel airlift technology which is simple, scalable, inexpensive to use and proven to out-perform cell culture in flasks. The CellexusBags, which are the unique single-use, disposable cell culture bags in which cells are grown in the CellMaker Regular system, enable fast set-up times and eliminate cleaning requirements. The CellMaker Regular very efficiently aerates the CellexusBag with controlled air flow providing oxygen for cell growth and gentle and effective mixing to maintain cells in suspension. Pressure control enhances oxygen availability to cells as well as decreases foaming and temperature control enables production of high yields of soluble protein under optimal conditions.
Mr Bob Cumming, Cellexus Limited General Manager, stated "We are very pleased that Dr Primrose will be joining the Cellexus Board. His wealth of knowledge in the bioprocess market sector will be a valuable asset as we continue to grow. He is a highly experienced executive who has held senior management positions at Searle Research & Development as well as Amersham International. In the past he has also held Non-Executive positions at Codon Pharmaceuticals, Adaptive Biosystems, the Health Protection Agency and Vistatec York Ltd. He is currently a Non-Executive Director at Novolytics Ltd, Immune Targeting Systems and Lab901 Limited." Dr Primrose, added "I am very pleased to join the Cellexus team and look forward to working with the Board as we further progress Company strategy and drive growth. Cellexus is very well positioned to gain significant market share with the Company's range of very innovative single-use, disposable bioreactor products which are highly important to customers in the bioprocess field. "